Asuragen, Inc. Reports Results from a Multi-Center Study on Fragile X Gene Expansion Risk at the Annual Meeting of the American College of Medical Genetics
AUSTIN, Texas--(BUSINESS WIRE)--Asuragen, Inc. announced today preliminary results revealing the risks of expansion for intermediate and small premutation fragile X alleles in more than 1,000 clinical samples that will be presented at the 2011 Annual Meeting of the American College of Medical Genetics being held in Vancouver, British Columbia from March 16-20th. The study, performed in collaboration with leading fragile X research centers at the New York Institute for Basic Research in Developmental Disabilities, Rush University Medical Center, Emory University School of Medicine, and the M.I.N.D. Institute at the University of California Davis, applied Asuragen’s proprietary and novel FMR1 genotyping methods to determine the incidence and nature of repeat expansion as a function of the underlying AGG structure. These results may have important implications for the interpretation of risk and genetic counseling for the estimated 1 million fragile X carriers in the US.